Related Experiment Videos
Immunotherapy with monoclonal antibodies in metastatic melanoma
T A Steffens1, D F Bajorin, A N Houghton
1Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Abstract:
Therapy for metastatic melanoma has been disappointing to date. Treatment with chemotherapy only uncommonly results in complete responses and rarely results in long-term survivors. The identification of human melanoma cell surface antigens has led to the development of an array of mouse monoclonal antibodies (MAb) for use in the diagnosis and therapy of patients with metastatic melanoma. Strategies utilizing MAbs based on immunologic approaches have been developed. Naked MAbs directed against glycoprotein surface antigens or conjugated to toxins or radionuclides have shown little biologic or clinical activity. However, phase I studies of MAb directed against glycolipid antigens have yielded objective tumor shrinkage with occasional complete responses. Severe toxicity has been seen infrequently. Possible anti-tumor mechanisms include complement activation and antibody-dependent cellular cytotoxicity utilizing natural killer cells or monocytes as effector cells. Strategies to enhance the anti-tumor effects of MAb, including combinations with cytotoxic agents and cytokines, have been introduced with limited success thus far. The development of a human IgG anti-mouse antibody has been seen in nearly all treated patients. A new generation of MAb engineered to overcome the immunogenicity of mouse MAb and to enhance immune effector function will soon enter clinical trials.
Insights
Monoclonal antibodies targeting melanoma cell surface antigens show promise, with some glycolipid-targeting antibodies achieving tumor shrinkage. Further research aims to improve efficacy and reduce immune responses for better metastatic melanoma therapy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Metastatic melanoma treatment remains challenging, with chemotherapy offering limited long-term survival benefits.
- Identification of melanoma cell surface antigens has enabled the development of mouse monoclonal antibodies (MAb) for therapeutic strategies.
Purpose of the Study:
- To review the development and clinical activity of monoclonal antibodies (MAb) in metastatic melanoma therapy.
- To explore potential anti-tumor mechanisms and strategies for enhancing MAb efficacy.
Main Methods:
- Review of strategies utilizing naked MAbs against glycoprotein or glycolipid antigens.
- Analysis of MAb conjugation with toxins or radionuclides.
- Evaluation of combination therapies with cytotoxic agents and cytokines.
Main Results:
- Naked MAbs against glycoproteins showed limited activity; however, MAbs targeting glycolipid antigens demonstrated objective tumor shrinkage and occasional complete responses in Phase I studies.
- Anti-tumor effects may involve complement activation and antibody-dependent cellular cytotoxicity.
- Human anti-mouse antibody development was observed in most patients, indicating immunogenicity.
Conclusions:
- Monoclonal antibodies targeting glycolipid antigens represent a promising therapeutic avenue for metastatic melanoma, despite challenges with immunogenicity.
- Newer generations of engineered MAbs aim to overcome immunogenicity and enhance effector functions for improved clinical outcomes.